FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Indication

Peripheral Artery Disease

Clinical and regulatory intelligence for Peripheral Artery Disease with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Assets: 0

Relevant assets

No related entities indexed yet.

Relevant companies

Abbott →

Recent signals(2)

ClinicalAugust 8, 2026

Study on IVUS vs Angiography in Peripheral Artery Disease Revascularization

This study aims to evaluate the effectiveness of intravascular ultrasound (IVUS) compared to angiography in preventing major adverse limb events in patients with chronic limb-threatening ischemia (CLTI).

ClinicalJuly 4, 2026

Study on Orbital Atherectomy for Critical Limb-Threatening Ischemia Launched in Europe

The ORACLE study will evaluate the effectiveness of orbital atherectomy in patients with critical limb-threatening ischemia across Europe.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Cardiovascular →

Peripheral Artery Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.